Spectral AI launches DeepView clinical study to support FDA label expansion for head, hands and feet burns

• Spectral AI launched a clinical study to support expanding the DeepView System’s FDA-cleared burn label to head, hand, foot burns.
• No clinical results have been presented; the trial is designed to generate evidence for a future label expansion submission.
• The study aims to support broader use in anatomically complex burn areas by improving treatment planning decisions.
• First site initiation visit completed at Pinderfields Hospital in the UK, enabling patient enrollment to begin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010830PRIMZONEFULLFEED9837833) on October 01, 2026, and is solely responsible for the information contained therein.